幽门螺杆菌根除治疗预防胃癌:系统综述与荟萃分析
该系统综述与荟萃分析更新至2020年2月,纳入10项随机对照试验。在健康人群中,根除治疗降低胃癌发生率(RR=0.54)和胃癌死亡率(RR=0.61);在胃肿瘤内镜下黏膜切除术后患者中亦降低未来胃癌发生率(RR=0.49)。
要点
- 健康人群根除幽门螺杆菌可降低胃癌发生率和胃癌死亡率。
- 胃肿瘤内镜黏膜切除术后根除治疗可降低未来胃癌发生率。
- 全球筛查与治疗可能获得大量伤残调整生命年。
核心结论
- 中等证据提示幽门螺杆菌根除治疗可降低东亚国家健康个体和胃肿瘤患者的胃癌发生率,并可能降低胃癌相关死亡率。
研究设计与样本
- 系统综述与荟萃分析,检索截至2020年2月的随机对照试验,纳入10项RCT。
- 7项RCT纳入8323名健康幽门螺杆菌阳性个体,3项RCT随机分配1841例胃肿瘤患者。
- 对照组接受安慰剂或无治疗,随访至少2年。
主要发现
- 健康个体中,根除治疗降低胃癌发生率(RR=0.54;95% CI 0.40至0.72;NNT=72)。
- 健康个体中,根除治疗降低胃癌死亡率(RR=0.61;95% CI 0.40至0.92;NNT=135),但未影响全因死亡率。
- 胃肿瘤患者中,根除治疗降低未来胃癌发生率(RR=0.49;95% CI 0.34至0.70;NNT=21)。
- 不良事件报告不完整。
关键数值与推荐
- 健康个体胃癌发生率RR=0.54(95% CI 0.40至0.72),NNT=72。
- 健康个体胃癌死亡率RR=0.61(95% CI 0.40至0.92),NNT=135。
- 胃肿瘤患者未来胃癌发生率RR=0.49(95% CI 0.34至0.70),NNT=21。
临床怎么用
- 对幽门螺杆菌阳性的健康个体可考虑根除治疗以降低胃癌发生风险。
- 胃肿瘤内镜下黏膜切除术后幽门螺杆菌阳性患者可考虑根除治疗以降低异时胃癌风险。
局限性
- 不良事件报告不完整。
- 证据主要来自东亚国家。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gastric cancer is strongly associated with Helicobacter pylori (H. pylori). We conducted a previous systematic review and meta-analysis that suggested eradication therapy reduced future incidence of gastric cancer, but effect size was uncertain, and there was no reduction in gastric cancer-related mortality. We updated this meta-analysis, as more data has accumulated. We also evaluated impact of eradication therapy on future risk of gastric cancer in patients having endoscopic mucosal resection for gastric neoplasia. DESIGN: We searched the medical literature through February 2020 to identify randomised controlled trials (RCTs) examining effect of eradication therapy on subsequent occurrence of gastric cancer in healthy H. pylori-positive adults, and in H. pylori-positive patients with gastric neoplasia undergoing endoscopic mucosal resection. The control arm received placebo or no treatment. Follow-up was for ≥2 years. We estimated the relative risk (RR) number needed to treat (NNT), and evaluated the disability-adjusted life-years (DALYs) gained from screening from the meta-analysis. RESULTS: We identified 10 RCTs, seven recruited 8323 healthy individuals, and three randomised 1841 patients with gastric neoplasia. In healthy individuals, eradication therapy reduced incidence of gastric cancer (RR=0.54; 95% CI 0.40 to 0.72, NNT=72), and reduced mortality from gastric cancer (RR=0.61; 95% CI 0.40 to 0.92, NNT=135), but did not affect all-cause mortality. These data suggest that 8 743 815 DALYs (95% CI 5 646 173 to 11 847 456) would be gained if population screening and treatment was implemented globally. In patients with gastric neoplasia, eradication therapy also reduced incidence of future gastric cancer (RR=0.49; 95% CI 0.34 to 0.70, NNT=21). Adverse events were incompletely reported. CONCLUSION: There is moderate evidence to suggest that H. pylori eradication therapy reduces the incidence of gastric cancer in healthy individuals and patients with gastric neoplasia in East Asian countries. There also appears to be a reduction in gastric cancer-related mortality.
引用
- Ford AC, Yuan Y, Moayyedi P, et al. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020. PMID: 32205420. doi:10.1136/gutjnl-2020-320839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。